Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF

PURPOSE: Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smith, B. Douglas, Jones, Richard J., Cho, Eunpi, Kowalski, Jeanne, Karp, Judith E., Gore, Steven D., Vala, Milada, Meade, Brooke, Baker, Sharyn D., Zhao, Ming, Piantadosi, Steven, Zhang, Zhe, Blumenthal, Gideon, Warlick, Erica D., Brodsky, Robert A., Murgo, Anthony, Rudek, Michelle A., Matsui, William H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033102/
https://ncbi.nlm.nih.gov/pubmed/20598742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2010.06.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados